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Scygonadin is an anionic antimicrobial peptide recently identified from the seminal plasma of Scylla serrata.
To gain more detailed information on its antimicrobial activity, scygonadin mature peptide was expressed
in Escherichia coli in order to obtain a large quantity of biologically active product. An approximately 43 kDa
fusion protein CKS-scygonadin was obtained in a highly stable and soluble form. The soluble component of
the fusion CKS-scygonadin was purified by immobilized metal affinity chromatography (IMAC). A single
11 kDa recombinant scygonadin was cleaved from CKS-scygonadin and purified from the cleavage mixture
using an affinity chromatography column with a yield of 10.6 mg/L. Alternatively, a recombinant scygona-
din was purified from pET28-scygonadin by one-step Ni2+ affinity chromatography and 65.9 mg/L pure
recombinant scygonadin was obtained which was higher than that purified from pTrc-CKS/scygonadin in
bacteria culture. The recombinant scygonadin was confirmed using SDS–PAGE analysis and MS-fingerprint-
ing. Both recombinant products of scygonadin from different expressed plasmids showed the activity
against both Gram-positive and Gram-negative bacteria, but no activity against yeast and fungi tested.
The kinetic studies showed that the recombinant scygonadin was strong active against Staphylococcus aur-
eus and the killing of S. aureus appeared time and dose dependent. Considering the quantity of recombinant
product and the applicability of purification, the pET28-scygonadin expression system is a better choice to
produce large quantities of recombinant scygonadin for commercial use in future. This is the first report on
the heterologous expression of antimicrobial peptide scygonadin in E. coli.
 2009 Elsevier Inc. All rights reserved.Introduction
Antimicrobial peptides (AMPs)1 are the major component of the
innate immune system of many organisms and play an important
role in protecting the host species from microbial invasion. Like
other crustaceans [1], Scylla serrata may rely solely on innate im-
mune mechanism to survive in a complex marine environment.
In crustaceans, there have been several antimicrobial peptides so
far reported which were isolated from the shore crab Carcinus mae-
nas [1,2], the blue crab Callinectes sapidus [3] and from the Pacific
white shrimp Litopenaeus vannamei [4], etc. However, only a few
AMPs have been identified so far from S. serrata, including scyllin
from hemolymph [5], scygonadin [6,7] and a 20-kDa protein from
the seminal plasma of S. serrata [8], and crustin from Scylla param-
amosain [9]. Therefore, elucidation of AMPs or their homologs willll rights reserved.
s; IMAC, immobilized metal
ctopyranoside; TrxA, thiore-
ory concentration.provide valuable data for us in depth understanding of the mecha-
nism of innate immunity in S. serrata.
Scygonadin which was originally isolated from the seminal plas-
ma of S. serrata, has shown antibacterial activity against Micrococcus
leteus and Aeromonas hydrophila [6] and was thought it is an anionic
AMP [6,7]. Its cDNA and genomic DNA have been revealed and this
peptide shows a specific expression in male crab [7]. To characterize
this peptide in details, it is necessary to elucidate its antimicrobial
spectrum. However, it was difficult to obtain sufficient amounts of
scygonadin for determination of its antimicrobial spectrum and for
study of its other potential biological functions using our previous
purification procedure of this native protein from S. serrata [6]. Thus,
heterologous production of scygonadin is required.
It is reported that some antimicrobial peptides have been ex-
pressed in prokaryocyte or eukaryocyte systems and recombinant
products were obtained for examining their antimicrobial activity,
such as penaeidin in Saccharomyces cerevisiae [10], a scallop big
defensin in Pichia pastoris [11], a human hepcidin in Escherichia coli
[12], and an insect cecropin in E. coli [13]. Due to the ease of trans-
formation, cloning and high cell density cultivation, E. coli is by far
the most widely used microorganism for the production of recom-
110 H. Peng et al. / Protein Expression and Purification 70 (2010) 109–115binant proteins and enzymes [14,15] and it is a useful tool to
obtain recombinant protein through a prokaryotic expression
system [16]. Recombinant AMPs can be used to analyze antimicro-
bial activity against bacteria and probably no difference in antibac-
terial activity was observed among the recombinant and natively
purified AMPs. This was confirmed in the previous study of shrimp
panaeidin [10].
This study aims to express the mature peptide of scygonadin in
E. coli, establish a high prokaryotic expression system to obtain
large quantities of the recombinant scygonadin, and also examine
the antimicrobial activity of scygonadin targeting pathogenic
organisms.Materials and methods
Plasmid construction
A 306 bp sequence coding the mature peptide of scygonadin
was inserted into pTrc-CKS (Gene Power Lab Ltd.) through the BglII
and XbaI sites. The expression vector pTrc-CKS carries a recombi-
nant 3C protease recognition site: Leu Glu Val Leu Phe Gln;Gly
Pro, and a His-tag at the C-terminus. The resulting pTrc-CKS/scy-
gonadin was confirmed by PCR and DNA sequencing.
The inserted interest encoding the mature peptide of scygona-
din was based on the cDNA sequence of scygonadin, which was
amplified by RT-PCR [7]. The primers were based on the analysis
of multiple cloning sites of the expression vector pTrc-CKS. The for-
ward primer (50-GCCGAGATCTGGCCAGGCACTCAACAA-30) intro-
duced a BglII site (underlined). The reverse primer was designed
as (50-GCGTCTAGAGTAAGAAGCAATCCAGT-30), with an endonucle-
ase site XbaI (underlined), corresponding to nucleotides 129–
145 bp and 418–434 bp of scygonadin cDNA (GenBank Accession
No. AY864802), respectively. The PCR product was digested with
BglII and XbaI, and ligated into the BamHI/NheI-digested pTrc-
CKS. The interest fragment inserted into pTrc-CKS included both
the scygonadin mature peptide sequence and the coding sequence
for some residues at the N-terminus of CKS, plus a C-terminal
hexa-histidine tag. The resulting pTrc-CKS/scygonadin was verified
by PCR amplification of clones and DNA sequencing.
Alternatively, another expression vector pET-28a (Novagen)
was adopted for constructing a high expressed plasmid. Scygona-
din mature sequence was amplified by PCR. The primers used were
50-GCGCCATGGGCCAGGCACTCAACAA-30 (forward primer with an
endonuclease site NcoI) and 50-GGGCTCGAGGTAAGAAGCAATC-
CAGT-30 (reverse primer with an endonuclease site XhoI). The
PCR products were digested by NcoI and XhoI, and then cloned into
pET-28a digested by the same restriction enzymes. The expressed
plasmid pET28-scygonadin was constructed with a C-terminal
hexa-histidine tag and confirmed by DNA sequencing.Expression of CKS-scygonadin and scygonadin(pET)
A single colony of E. coli TOP10F0 transformed with pTrc-CKS/
scygonadin was inoculated into LB medium containing 120 lg/
mL ampicillin, and then cultured at 37 C until OD600 reached
0.6. A single colony of E. coli BL21(DE3)pLysS with pET28-scygon-
adin was grown in LB medium containing 50 lg/mL kanamycin
and 0.5% glucose at 37 C until OD600 reached 0.2–0.3. Both CKS-
scygonadin and scygonadin(pET) were induced by adding 0.5 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) to the culture. These
medium were incubated at 28 C for 3 h and shaken at 180 rpm.
The cells were harvested and subsequently the suspension was
lyzed using sonication (180 for 5 s, interval 10 s, 180 w) and
the lysate was centrifuged at 10,000 rpm for 15 min. The superna-
tant was collected for analysis of fusion protein using SDS–PAGE.Preparation of CKS-scygonadin and scygonadin(pET) from the
supernatant and its absorption on Super Chelating Resin
A highly expressing soluble component of the recombinant
pTrc-CKS/scygonadin or pET28-scygonadin colony, which was care-
fully selected by analysis of the quantity in the supernatant, was
inoculated into 2–3 L of LB medium. The cells were harvested and
resuspended in pre-cold PBS. Then, the suspension was cooled with
ice and lyzed in an ice/water bath using sonication. The supernatant
containing the soluble component of CKS-scygonadin or scygona-
din(pET) was collected by centrifugation at 12,000 rpm for 15 min
at 4 C. The collected supernatant was filtered with a 0.45 lm filter
membrane to be prepared for purification using IMAC.The Purification of CKS-scygonadin using IMAC
The purification procedure was carried out using an AKTA Puri-
fier 100 (GE Healthcare Life Sciences). The collected supernatant
was filtered with a 0.45 lm filter membrane and then passed
through an affinity chromatography column (GE Healthcare Life
Sciences) equilibrated with binding buffer (20 mM PBS, 500 mM
NaCl, and 10 mM imidazole, pH 8.0). The column was washed with
binding buffer to remove contaminating proteins and the recombi-
nant fusion proteins were eluted by 150 mM imidazole. The eluted
fractions were collected and dialyzed in a 50 mM Tris–Cl buffer
(50 mM Tris, 50 mM NaCl, pH 8.0). The protein concentration
was determined as described by Bradford [17].3C protease (P3C) cleavage
To release scygonadin from the fusion protein CKS-scygonadin,
P3C (Novagen) was added to cleave the fusion protein in the ratio
of 1 U/100 lg fusion protein in 50 mM Tris–Cl buffer. The reaction
mixture was incubated at 4 C for 24 h.Purification of the recombinant scygonadin from the fusion protein
using IMAC
The mixture proteins including CKS and scygonadin were
loaded on the affinity chromatography column equilibrated with
binding buffer (20 mM PBS, 500 mM NaCl, and 10 mM imidazole,
pH 8.0). The unbound proteins were washed by 10 mM imidazole
and 60 mM imidazole. The recombinant scygonadin was eluted
by 250 mM imidazole. The eluted fractions were collected and
finally dialyzed in a 20 mM Tris–Cl buffer (20 mM Tris, 20 mM
NaCl, pH 8.0) before antimicrobial activity was tested.The purification of scygonadin(pET) using IMAC
Recombinant scygonadin(pET) was purified using the procedure
similar to the second purification for the recombinant CKS-scygona-
din. The unbound proteins were washed by 10 mM imidazole and
60 mM imidazole. And finally dialyzed in a 20 mM Tris–Cl buffer
(20 mM Tris, 20 mM NaCl, pH 8.0) before antimicrobial activity was
tested.Characterization of the purified scygonadin with Matrix assisted laser
desorption ionization-time of flight mass spectrometry
Analysis of the recombinant scygonadin was carried out on a
Bruker (Bremen) Biflex MALDI-TOF mass spectrometer as de-
scribed previously [6].
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Antibacterial assays were performed with ten strains of bacteria
including Gram-positive Staphylococcus aureus, Staphylococcus epi-
dermidis, M. leteus, Corynebacterium glutamicum, Bacillus subtilis
and Bacillus cereus, and Gram-negative Escherichia coli, A. hydrophil-
a, Vibrio harveyi, Vibrio alginolyticus. The antibacterial activities of
the recombinant scygonadin were tested at pH 7.4. The bacteria
were cultured on Mueller–Hinton broth medium and Difco marine
broth was used. Determination of minimum inhibitory concentra-
tion (MIC) values was performed by the liquid growth inhibition
assays as previously described [18,19]. Briefly, bacteria were di-
luted in 10 mM NaPB to A600 = 0.003(3–6  105 CFU/mL). The as-
say mixture consisted of 50 lL diluted purified peptide, 30 lL
diluted bacteria suspension and 20 lL culture media. After 24 h
of incubation at 28 C, MIC was calculated as the lowest peptide
concentration yielding no detectable growth. This assay was per-
formed in triplicate.
Yeast was grown in YPG medium (yeast extract 1%, peptone 1%,
glucose 2%). Filamentous fungi was grown in 1/2 Potato Dextrose
Broth [19]. Briefly, the assay mixture contained 50 lL diluted puri-
fied peptide, 30 lL diluted yeast (103 CFU/well) or fungi suspen-
sion (103 spores/well) and 20 lL its corresponding broth. The
antimicrobial activities were evaluated after 48 h of incubation at
28 C, by assessment of visible turbidity in each well in the plate.
Each assay was performed in triplicate.
Kill-curve studies
Bactericidal or bacteriostatic effect was performed using S. aur-
eus as described previously [19,20]. Recombinant scygonadin(pET)
(30 or 60 lM, 2 MIC or 4 MIC) was incubated with S. aureus as
described above. At each time point of incubation, 6 lL was taken
from the mixture, serially diluted in 10 mM NaPB and plated on
nutrition broth agar. Plates were incubated at 37 C for 24 h. Mean-
while, an equivalent volume of 20 mM Tris–Cl buffer without re-
combinant scygonadin was added to the control tube. The
percentage of CFU was defined relative to the CFU obtained in
the control (100% cfu at 0 min).
Results
Construction of recombinant expression vectors of pTrc-CKS/
scygonadin and pET28-scygonadin
Scygonadin protein consists of a putative NH2-terminal signal
sequence (1–24) and a mature peptide (25–126) [7]. The scygona-
din mature peptide sequence was prepared by PCR, and the 306 bp
PCR product coding 102-aa peptide was cloned according to the
scygonadin cDNA sequence (GenBank Accession No. AY864802).
Considering a possibility of high toxicity of antimicrobial peptideFig. 1. Construction of the expression vector pTrc-Cagainst host cells as it is expressed in E. coli with soluble form, fu-
sion partners are normally used such as intein [21,22], light mero-
myosin (LMM) [23], and thioredoxin (TrxA) [13,24]. In this study
an expression vector pTrc-CKS was adopted, in which CKS as a fu-
sion protein is a soluble partner (CMP-3-deoxy-D-manno-octulo-
sonate cytidylyltransferase) at the upstream and a 6 His-tag as
a purification utility at the downstream (Fig. 1a). The mature pep-
tide sequence encoding 102 amino acids was ligated into a pTrc-
CKS expression vector to construct an expressed plasmid in which
the E. coli TOP10F0 harboring pTrc-CKS/scygonadin chimeric plas-
mid that will express a 43 kDa fusion polypeptide. Another
pET28-scygonadin plasmid expressing a single 11 kDa scygonadin
was designed using the similar procedure (Fig. 1b).
Expression of CKS-scygonadin and scygonadin(pET)
CKS-scygonadin was induced with 0.5 mM IPTG at 28 C for 3 h.
A fusion protein CKS-scygonadin (about 43 kDa) was expressed in
E. coli TOP10F0 and it was highly soluble as shown in Fig. 2. And
approximately 89.1 mg soluble CKS-scygonadin was obtained from
1 L of bacteria culture (Table 1). Similarly, a soluble component of
the recombinant scygonadin(pET) around 11 kDa polypeptide was
expressed in E. coli BL21(DE3)pLysS as shown in Table 2 and
approximately 97.5 mg soluble scygonadin(pET) was obtained
form 1 L of bacteria culture.
Purification of CKS-scygonadin and scygonadin(pET) by IMAC
In order to easily obtain the soluble component of the fusion
protein CKS-scygonadin, the supernatant was collected from the
sonicated crude extract of fusion protein after centrifugation, and
purified through a Ni2+-chelating-Sepharose column (GE Health-
care Life Sciences). To collect the fusion protein conjugated with
Ni2+ in the affinity chromatography column, a higher concentration
of imidazole was selected for washing through the column in order
to harvest the fusion protein elution peak. Because the collected fu-
sion protein mixture contained a higher concentration of imidaz-
ole, which may be toxic to bacterial cells, it is necessary to
remove the imidazole completely from the fusion protein collec-
tion. After dialysis, the imidazole was removed.
The fusion protein CKS-scygonadin was completely digested
after cleaved by 3C protease. Two clear bands approximately 32
and 11 kDa were detected as shown in Fig. 3, corresponding to
the estimated molecular weight for CKS and scygonadin, respec-
tively. Subsequently, the recombinant scygonadin was purified
using Ni2+-chelating-Sepharose column. As shown in Fig. 4, CKS
protein was washed in 10 mM imidazole of the loading buffer
(Fig. 4 fraction A, lane 1), and a little CKS and unspecific binding
proteins were then washed with 60 mM imidazole (Fig. 4 fraction
B, lane 2). Pure scygonadin was eluted with 250 mM imidazole
(Fig. 4 fraction C, lane 3). The eluted fractions were collected andKS/scygonadin (a) and pET28-scygonadin (b).
Fig. 2. SDS–PAGE analysis of CKS-scygonadin expression and the soluble product in
Escherichia coli TOP10F0 was carried out in a 15% (w/v) separation gel. The gel was
stained with Coomassie Brilliant Blue R-250. Lane M, low range protein marker (Bio
Basic Inc.); lane 1, the fusion partner CKS expression induced with IPTG for 3 h; lane
2, CKS-scygonadin expression induced with IPTG for 0 h as control; lane 3, CKS-
scygonadin expression induced with IPTG for 3 h; lane 4, sonicated supernatant
(soluble component) of induced cells.
Fig. 3. SDS–PAGE analysis of 3C protease cleavage of the recombinant fusion
protein CKS-scygonadin. Lane M, low range protein marker (Bio Basic Inc.); lane 1,
fusion protein CKS-scygonadin after purification; lane 2, protein sample after
cleavage reaction, upper band represents CKS, lower band represents the
recombinant scygonadin.
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Tris, PH 8.0) before antimicrobial activity was tested. Overall,
approximately 10.6 mg pure recombinant scygonadin were ob-
tained from the expressed fusion protein CKS-scygonadin in 1 L
of bacteria culture (Table 1).
The recombinant scygonadin(pET) was purified by one-step
Ni2+ affinity chromatography. Approximately 65.9 mg pure recom-
binant scygonadin were obtained, which was six times as much as
the production of pure scygonadin from pTrc-CKS/scygonadin in
1 L of bacteria culture (Table 2, Fig. 5).Table 1
Summary of approximately yield of total and the recombinant scygonadin from pTrc-CKS
Purification step Total p
Sonicated supernatant 270
The first nickel affinity chromatography step 78.3
After dialysis and cleavage, the second affinity chromatography step 11
a Protein concentration was determined using Bradford’s method.
b Protein or peptide purity was estimated by SDS gel scanning.
Table 2
Summary of approximately yield of total and the recombinant scygonadin from pET28-scy
Purification step Total proteina (mg)
Sonicated supernatant 250
One-step affinity chromatography and after dialysis 69.4
a Protein concentration was determined using Bradford’s method.
b Protein or peptide purity was estimated by SDS gel scanning.MS-fingerprint of the recombinant scygonadin
The 11 kDa purified recombinant scygonadin was sent for MS-
fingerprinting. The MS-fingerprinting result for scygonadin is
shown in Fig. 6, which corresponds with our previous determina-
tion of this peptide [6], demonstrating that the pure recombinant
protein is the expected scygonadin.Antimicrobial assay
The antimicrobial activities of the recombinant scygonadin
were determined against a panel of microorganisms using MIC.
The recombinant CKS-scygonadin fusion protein showed the value
of MIC over 60 lM (data not shown in table) indicating no activity
against all the tested bacterial strains. The purified recombinant
scygonadin from pTrc-CKS/scygonadin showed a potent activity
against A. hydrophila (30–60 lM) and some Gram-positive bacteria
(7.5–30 lM) but no activity against yeast and fungi tested/scygonadin after purification with affinity chromatography (1 L E. coli culture).




gonadin after one-step purification with affinity chromatography (1 L E. coli culture).
Fusion protein (mg) Purityb (%) Yield (%)
97.5 39 100
65.9 95 68
Fig. 4. Purfication of His-tagged scygonadin from the recombinant CKS-scygonadin. HPLC elution of scygonadin by Ni2+ affinity chromatography showing the programmed
imidazole gradient and the resulting A280 nm reading and SDS–PAGE gel showing HPLC purification of scygonadin.
Fig. 5. SDS–PAGE analysis of the recombinant scygonadin(pET) expressed in
Escherichia coli BL21(DE3)pLysS. The purified soluble product was carried out in a
15% (w/v) separation gel. The gel was stained with Coomassie Brilliant Blue R-250.
Lane M, low range protein marker (Bio Basic Inc.); lane 1, scygonadin(pET) expression
induced with IPTG for 0 h as control; lane 2, scygonadin(pET) expression induced with
IPTG for 3 h; lane 3, sonicated supernatant (soluble component) of induced cells. Lane
4, product of inclusion bodies lane 5, scygonadin(pET) after purification.
Fig. 6. MS-fingerprint of scygonadin. The mass of each peptide fragment was determined
a-cyano-4-hydroxycinnamic acid. In the table, D mass means the difference between the
the peptide. Position represents the corresponding position matching to the predicted s
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pET28-scygonadin showed similar antimicrobial activity but more
active against S. aureus than scygonadin from pTrc-CKS/scygonadin
(Table 3). The results indicate that the antimicrobial activity of scy-
gonadin is prone to target-specific.
Kinetics of killing of S. aureus by the recombinant scygonadin
In the kinetic study, a sensitive bacterial strain S. aureus was
used to evaluate bactericidal or bacteriostatic activity of the puri-
fied recombinant scygonadin from the pET28-scygonadin plasmid.
S. aureus was incubated with the recombinant scygonadin at a con-
centration 2–4 times over the MIC value (30–60 lM). The bacteri-
cidal activity of this peptide was assessed by plating cultures and
counting CFUs after incubation at 37 C for 24 h (Fig. 7). In the long
term analysis, when S. aureus was incubated with the purified
recombinant scygonadin at a concentration 30 lM (2 MIC) and
60 lM (4 MIC), respectively, over 97% S. aureus were killed after
15 min (Fig. 7). Subsequently, the killing kinetics of scygonadin
was measured within a 15-min incubation period. In the short
term analysis, approximately 50% S. aureus were killed after
3 min at a concentration 60 lM (4 MIC) and nearly 6 min at
30 lM (2 MIC). And approximately 90% S. aureus were killed atby MALDI-TOF MS and is displayed in the graph. The matrix used in the analysis is
mass observed and the predicted mass, MC is the number of the missed cleavage for
cygonadin mature peptide sequence (GenBank Accession No. Q5D710).
Table 3
Antimicrobial activity of recombinant scygonadin.
Microorganisms CGMCC No.c Scygondin




Aeromonas hydrophila 1.2017 30[a]–60[b] 30–60
Escherichia coli 1.2389 >60 >60
Vibrio harveyi 1.1593 >60 >60
Vibrio alginolyticus 1.1833 >60 >60
Gram-positive bacteria
Micrococcus leteus 1.634 7.5–15 7.5–15
Staphylococcus aureus 1.363 15–30 7.5–15
Corynebacterium glutamicum 1.1886 15–30 15–30
Staphylococcus epidermidis 1.2429 >60 >60
Bacillus subtilis 1.108 >60 >60
Bacillus cereus 1.447 >60 >60
Filamentous fungi
Aspergillus niger 3.316 >60 >60
Fusarium solani 3.5840 >60 >60
Yeast
Candida albicans 2.2411 >60 >60
Pichia pastoris GS115 Invitrogene >60 >60
MIC values are expressed as the interval of concentration [a]–[b], where [a] is the highest concentration tested at which microbial growth can be observed, and [b] is the
lowest concentration yielding no detectable microbial growth(n = 3).
c CGMCC No. means China General Microbiological Culture Collection Center.
d MIC, minimal inhibitory concentration.
e Pichia pastoris GS115 was purchased from Invitrogen.
Fig. 7. Kinetics of killing S. aureus by recominant scygonadin. Recombinant scygonadin at 2MIC (30 lM), 4MIC (60 lM) or 20 mM Tris–Cl buffer (control) was added to a log
phase culture of S. aureus. The percentage of CFU was defined relative to the CFU obtained in the control (100% at 0 min). Each point represents the average of three
independent experiments, and the vertical bars represent the mean ± SD and they were analyzed by 2-way ANOVA followed by Tukey post hoc test. The same letters (a, b, c, d,
e, f) or (A, B, C, D, E) indicate no significant difference between different time points and different letters indicate statistically significant differences (p 6 0.05) between time
points.
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(4 MIC) (Fig. 7). Thus the killing of the S. aureus by the recombi-
nant scygonadin showed time and dose dependent.4. Discussion
Due to the difficulty of purifying native scygonadin from the go-
nads of S. serrata, large production of this AMP in an E. coli system
is required in order to allow further investigation of its antimicro-
bial spectrum and commercial use in aquaculture in future. Esche-
richia coli is a good choice as an expression host but the
recombinant AMPs might be active against it. To avoid the toxicity
of the recombinant scygonadin to the host cells and to obtain the
soluble expressed recombinant product, an expression vector
pTrc-CKS was used in this study, in which the CKS protein provedto be stable and a highly soluble partner to fuse with the target
protein [25,26]. As expected, the resulting recombinant CKS-scy-
gonadin was highly expressed in E. coli TOP10F0 and the soluble
component was obtained as shown in Fig. 2. The result showed
that the production of purified scygonadin from pTrc-CKS/scygon-
adin is not as high as we expected, which lead us to try to construct
another expression vector pET28-scygonadin. The result showed
that the recombinant scygonadin(pET) is higher soluble, most of
scygonadin existed in sonicated supernatant rather than in inclu-
sion bodies (Fig. 5). The production of the pure scygonadin from
pET28-scygonadin was six times as much as that from pTrc-CKS/
scygonadin, and also the purification procedure of the recombinant
scygonadin from pET28-scygonadin was simpler with only one-
step Ni2+ affinity chromatography (Tables 1 and 2) than that from
pTrc-CKS/scygonadin. Thus, it would be a better choice to express
scygonadin in pET28-scygonadin vector. In the study, we observed
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tion when the host cells were induced at OD600 0.2–0.3. If the cell
density was over 0.6 at OD600, the soluble scygonadin will be obvi-
ously decreased (data not shown).
In the study, the purified recombinant scygonadin exhibited
obvious antimicrobial activity against M. leteus, S. aureus, C. glutam-
icum and A. hydrophila (Table 3), demonstrating that this peptide
possesses the characteristic of activity against both Gram-positive
and Gram-negative bacteria, but no activity against yeast and fungi
tested. As observed in previous studies on the activity of some AMPs,
such as dermaseptins [27] or penaeidin [10], scygonadin had a spe-
cific antibacterial action which highly depended on the bacteria
tested. We previously found that the native purified scygondin
was active against M. leteus and A. hydrophila [6]. The purified native
scygonadin (12 lM) showed antibacterial activity (with a killing
index of nearly 90%) against the Gram-positive bacterium M. leteus
using liquid growth inhibition assays. In this study, the purified
recombinant scygonadin displayed a similar activity against M. le-
teus (MIC 7.5–15 lM). The result of activity against M. leteus ob-
tained from the recombinant scygonadin is consistent with our
previous observation using the purified native scygonadin [6]. We
presumed that the 6 His-tag at C-terminus might have not signifi-
cant influence to the antimicrobial activity of the recombinant scy-
gonadin. In view of this, expressing the recombinant scygonadin
through a prokaryotic expression system would be an applicable
way to be used for assessment of its antimicrobial activity.
To our knowledge, no information concerning the in vitro anti-
microbial activity was derived from the sex-specific AMPs of crus-
taceans. The E. coli expression system developed in this study was
shown to be appropriate for the production of large amounts of ac-
tive scygonadin. Scygonadin can be highly expressed in a soluble
form through the recombinant constructs of pTrc-CKS/scygonadin
and pET28-scygonadin expression vectors. The recombinant prod-
uct can be easily purified through IMAC. Considering the quantity
of recombinant product and the applicability of purification, we
suggest that the pET28-scygonadin expression system is much bet-
ter for commercial use in future. This is the first report on the het-
erologous expression of antibacterial peptide scygonadin in E. coli.
This recombinant scygonadin displayed antibacterial activity sim-
ilar to the native one against bacteria which allowed us to perform
a study of its antimicrobial activity.
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